Meningococcemia secondary prevention: Difference between revisions
No edit summary |
No edit summary |
||
| Line 12: | Line 12: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Needs overview]] | |||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
Revision as of 15:54, 15 February 2013
|
Meningococcemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Meningococcemia secondary prevention On the Web |
|
American Roentgen Ray Society Images of Meningococcemia secondary prevention |
|
Risk calculators and risk factors for Meningococcemia secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Secondary Prevention
The most important form of prevention is a vaccine against Neisseria meningitidis. Different countries have different strains of the bacteria and therefore use different vaccines. Five serogroups, A, B, C, Y and W135 are responsible for virtually all cases of the disease in humans. Vaccines are currently available against four of the five strains, and a vaccine against the B strain is in development. Menactra and Menomune are two commonly used vaccines. Unfortunately, there is currently no evidence that any of the current vaccines offer significant protection beyond three years.
Additionally, basic hygiene measures, such as hand washing and not sharing drinking cups, can reduce the incidence of infection by limiting exposure.
When a case is confirmed, all close contacts with the infected person can be offered antibiotics to reduce the likelihood of the infection spreading to other people.